322 related articles for article (PubMed ID: 33054820)
21. The Trans-Pacific Partnership and pharmaceutical innovation.
Freeman RA
Res Social Adm Pharm; 2016; 12(4):633-7. PubMed ID: 26803645
[TBL] [Abstract][Full Text] [Related]
22. Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
Luo J; Kesselheim AS
AMA J Ethics; 2016 Jul; 18(7):727-35. PubMed ID: 27437823
[TBL] [Abstract][Full Text] [Related]
23. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
Kingham R; Wheeler J
Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
[TBL] [Abstract][Full Text] [Related]
24. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership - a qualitative study of policy actors' views.
Townsend B
Global Health; 2021 Jul; 17(1):78. PubMed ID: 34238347
[TBL] [Abstract][Full Text] [Related]
25. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
Dunlop WCN; Staufer A; Levy P; Edwards GJ
Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
[TBL] [Abstract][Full Text] [Related]
26. The "Affordable Medicines" Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation.
Dobrova V; Ratushna K; Popov O; Bezruk A; Loboda I
Value Health; 2023 Mar; 26(3):359-369. PubMed ID: 36731746
[TBL] [Abstract][Full Text] [Related]
27. The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam.
Moir HVJ; Tenni B; Gleeson D; Lopert R
Glob Public Health; 2018 Apr; 13(4):400-413. PubMed ID: 27841097
[TBL] [Abstract][Full Text] [Related]
28. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
29. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
30. The ethics of intellectual property rights in an era of globalization.
Shah AK; Warsh J; Kesselheim AS
J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
[TBL] [Abstract][Full Text] [Related]
31. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence.
Wettstein DJ; Boes S
Health Policy; 2022 Feb; 126(2):112-121. PubMed ID: 35000803
[TBL] [Abstract][Full Text] [Related]
32. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
Velasquez G
Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
[TBL] [Abstract][Full Text] [Related]
33. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
[TBL] [Abstract][Full Text] [Related]
34. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
Shaw B; Mestre-Ferrandiz J
Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
[TBL] [Abstract][Full Text] [Related]
35. Drug Policy in Romania.
Radu CP; Pana BC; Furtunescu FL
Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
[TBL] [Abstract][Full Text] [Related]
36. Prices of new medicines: International analysis and policy options.
Vogler S
Z Evid Fortbild Qual Gesundhwes; 2022 Dec; 175():96-102. PubMed ID: 36372642
[TBL] [Abstract][Full Text] [Related]
37. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
38. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Assefa Y; Hill PS; Ulikpan A; Williams OD
Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
[TBL] [Abstract][Full Text] [Related]
39. Risk sharing in managed entry agreements-A review of the Swedish experience.
Andersson E; Svensson J; Persson U; Lindgren P
Health Policy; 2020 Apr; 124(4):404-410. PubMed ID: 32093981
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
